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Intracellular turnoverSkvorak et al. [1] demonstrated the therapeutic efﬁcacy of HTx in a murine model of iMSUD, conﬁrming
signiﬁcant metabolic improvement and survival. To determine the effect of HTx on extrahepatic organs, we
examined the metabolic effects of HTx in brain from iMSUD animals. Amino acid analysis revealed that HTx
corrected increased ornithine, partially corrected depleted glutamine, and revealed a trend toward
alloisoleucine correction. For amino acid and monoamine neurotransmitters, decreased GABA was partially
corrected with HTx, while the L-histidine dipeptide of GABA, homocarnosine, was decreased in iMSUD mice
and hypercorrected following HTx. Elevated branched-chain amino acids (BCAA; leucine, isoleucine, and
valine) in MSUD can deplete brain tyrosine and tryptophan (the precursors of monoamine neurotransmit-
ters, dopamine (DA) and serotonin (5-hydroxytryptamine; 5-HT)) through competition via the large neutral
amino acid transporter. HTx corrected decreased DA levels and the DA metabolite, 3-methoxytyramine, and
partially corrected the DA intermediate 3,4-dihydroxyphenylacetate (DOPAC) and 5-HT levels, despite
normal tyrosine and tryptophan levels in iMSUD mouse brain. We further observed enhanced intracellular
turnover of both DA and 5-HT in iMSUD mouse brain, both of which partially corrected with HTx. Our results
suggest new pathomechanisms of neurotransmitter metabolism in this disorder and support the therapeutic
relevance of HTx in iMSUD mice, while providing proof-of-principle that HTx has corrective potential in
extrahepatic organs.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Maple syrup urine disease (MSUD; OMIM 248600) is a heritable
amino acidemia characterized by accumulations of branched-chain
ketoacids (BCKAs), BCAAs and non-physiological L-alloisoleucine, the
latter pathognomonic for this disorder [2]. Varying degrees of, Rm 5118, 530 45th Street,
+1 412 692 7816.
n@mtu.edu (K.M. Gibson).
igan Technological University,
, MI49931-1295, USA. Tel.: +1
ll rights reserved.branched-chain ketoacid dehydrogenase (BCKDH) deﬁciency lead to
the subclassiﬁcations of MSUD, including classical, intermittent,
intermediate and thiamine-responsive forms. Treatment strategies
for MSUD are primarily dietary, focused on maintenance of normo-
physiological concentrations of L-leucine and other BCAAs. Addition-
ally, BCAAsmay compete with other large neutral amino acids (LNAA;
i.e., methionine, tyrosine, phenylalanine, tryptophan) for transport
across the blood brain barrier [3]. This observation has pathophysi-
ological relevance, since tyrosine and tryptophan are the immediate
precursors of the monoamine neurotransmitters, dopamine (DA) and
serotonin (5-hydroxytryptamine; 5-HT) (Fig. 1).
Maintenance of normophysiological leucine, isoleucine and valine
levels is achieved through limiting the ingestion of the three BCAAs.
Fig. 1. Abbreviated schematic diagram of reactions involved in the metabolism of the
monoamine neurotransmitters, dopamine and serotonin (not all steps are shown).
Abbreviations: L-DOPA, L-dihydroxyphenylalanine; 5-HTP, 5-hydroxytryptophan;
ALAAD, aromatic L-amino acid decarboxylase; DOPAC, 3,4-dihydroxyphenylacetic
acid; HVA, homovanillic acid; 3-MT, 3-methoxytyramine; 5-HIAA, 5-hydroxyindolea-
cetic acid.
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at times of catabolic crises. An alternative treatment approach is
orthotopic liver transplantation (OLT), which has excellent therapeu-
tic efﬁcacy [4]. OLT effectively lowers the circulating levels of BCAAs
and BCKAs. However, a limitation of OLT remains the shortage of
donor livers, and the potential for prolonged immunosuppression
intervention.
Successful OLT in MSUD patients suggests that hepatic cell-based
treatment approaches may have clinical relevance in this disorder.
Hepatocyte transplantation (HTx) has already proven to be a
promising approach for long-term therapy of genetic disorders with
a prominent hepatic phenotype, such as ornithine transcarbamylase
deﬁciency and glycogen storage disease [5,6]. Accordingly, Skvorak et
al. [1] evaluated HTx in a murine model of iMSUD [7]. These
investigators demonstrated engraftment of exogenous hepatocytes
into neonatal liver, a corresponding increase in liver BCKDH activity,
and a dramatic improvement of blood BCAAs in weanling iMSUD-HTx
mice. Despite these improvements in hepatic and peripheral
metabolism, little information exists on the effect of HTx on organs
beyond the liver, and few long-term studies of HTx in murine model
systems have been undertaken. Thus, in the current report we have
examined neurometabolic features of brains derived from iMSUD-HTx
animals that were transplanted in the neonatal period.
2. Materials and methods
Methodological details concerning HTx in iMSUD mice have been
recently reported [1]. Genotyping was performed using nestedFig. 2. β-Galactosidase staining of donor (left) and recipient (right) liver sections. Left: unﬁx
magniﬁcation) is depicted. Note the extensive blue staining indicative of β-galactosidase p
administration of hepatocytes [1]) revealed a diffuse punctuate staining pattern indicative
magniﬁcation).primers, as described [1]. All breeder pairs were mice homozygous
for the two previously described transgenes [7] and heterozygous for
the endogenous E2 subunit. Accordingly, wild-type (WT) mice also
expressed human E2, as described [1,7]. Line A iMSUDmice were used
for all experiments, on a mixed 129/C57 background [7]. Protocols for
β-galactosidase staining of isolated hepatocytes, as well as real-time
PCR for the murine E2 mRNA, were previously described [1]. Tissues
were harvested at weaning (DOL (day of life) 19–20), for both iMSUD
mice andWT control animals. Transplanted iMSUDmice (i.e., iMSUD-
HTx) were harvested at DOL 35 days of age. Our rationale for later
harvest of iMSUD-HTx tissues was based on our desire to estimate the
level of lifespan prolongation with HTx; other tissues (WT, iMSUD)
had already been harvested. By DOL 35, iMSUD-HTx animals appeared
unhealthy and lethargic, and tissues were accordingly harvested at
this time. At sacriﬁce, the skull was rapidly opened, the brain resected
(sagitally) in halves and tissue immediately stored at −80 °C until
analysis.
For amino acid analyses, brain tissue was extracted in ice-cold
SeraPrep (Pickering Laboratories, Mountain View, CA) and clariﬁed by
centrifugation. Amino acids were quantiﬁed by ion-exchange HPLC
analysis with ninhydrin post column detection [8]. GABA and
homocarnosine were determined in these same extracts employing
liquid chromatography–tandem mass spectrometry [9,10]. Mono-
amines in brain tissue were extracted using ice-cold perchloric acid.
Following centrifugation, monoamines were quantiﬁed by reversed-
phase HPLC analysis with electrochemical detection [11]. Metabolic
data are presented as mean±SEM and compiled using the Prizm
Graph 4.0 program. Statistical analysis was performed using one-way
ANOVA with Tukey post-hoc analysis. To be considered as having
been “corrected” (or “normalized”) with HTx, three criteria had to be
achieved for each metabolite: a) the value for iMSUD mice had to be
signiﬁcantly different from wild-type animals; b) the value for
iMSUD-HTx animals had to be signiﬁcantly different from that of
iMSUD animals; and c) there was no signiﬁcant difference between
the values observed for iMSUD-HTx and wild-type animals. When
only criteria a and c were met, the effect of HTx was considered to
have been “partial correction”.
3. Results
Viability of isolated hepatocytes was evaluated by trypan blue
exclusion, and only those preparations for which viability exceeded
80% were employed for HTx [1]. As shown in Fig. 2 (left), sectioned
liver (unﬁxed) from a newborn ROSA26+/− (age 1 day) mouseed liver section (Rosa26+/− donor, age 1 day) stained for β-galactosidase (30 μm, 10×
ositive cells. Right: unﬁxed iMSUD liver section (8 days of age, 24 h following second
of engrafted β-galactosidase positive cells into the recipient iMSUD liver (30 μm, 10×
Fig. 3. Selected whole brain amino acid concentrations in wild-type (WT), iMSUD (intermediate maple syrup urine disease) and iMSUD-HTx (hepatocyte transplanted) mice. Many amino acids that were not signiﬁcantly different by genotype
are not depicted. Parenthetical values indicate the number of subjects studied. ND, none detected. *p<0.05; **p<0.01; ***p<0.001, one-way ANOVA with Tukey post-hoc analysis as compared to WT subjects. Applying our deﬁnition of
metabolic correction or partial correction (see Materials and methods) revealed complete correction of ornithine with HTx (iMSUD vs. iMSUD-HTx, p<0.001) and partial correction of glutamine concentrations.
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Fig. 4. GABA and homocarnosine concentrations in whole brain. Details and statistical analyses as described in Fig. 2. Applying our deﬁnition of metabolic correction or partial correction
(seeMaterials and methods), GABA levels were partially corrected while homocarnosine was actually “hypercorrected” (iMSUD-HTx vs. WT, p<0.05; iMSUD-HTx vs. iMSUD, p<0.001).
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galactosidase staining. A punctuate blue staining pattern (Fig. 2,
right) from an iMSUD mouse (age 8 days, tissue obtained 24h
following second injection of hepatocytes) reveals dispersed regions
of engrafted hepatocytes into the recipient hepatic tissue (30 μm,
10×). Engraftment of β-galactosidase positive hepatocytes into
iMSUD liver is consistent with the two-fold increase in BCKDH
activity in iMSUD-HTx liver extracts that was previously documented,
in conjunction with the signiﬁcant improvement of branched-chain
amino acid levels in physiological ﬂuids from those animals [1].
Extensive amino acid proﬁling in extracts of whole brain revealed
a number of abnormalities (Fig. 3). For those physiological amino
acids not shown in Fig. 3, there were no differences with respect to
genotype. Levels of alloisoleucine showed a trend toward improve-
ment with HTx, although statistical signiﬁcance was not achieved
(Fig. 3). Of interest, elevated ornithine in iMSUD brainwas normalized
with HTx, and decreased glutamine showed partial correction (Fig. 3).
Conversely, there were no improvements for the signiﬁcant decreases
of amino acid transmitters in iMSUD brain, including glutamate and
aspartate, in conjunction with serine and alanine. We further
examined both GABA and the GABA conjugate, homocarnosine
(GABA:L-histidine dipeptide) (Fig. 4). Consistent with glutamate and
glutamine results, GABA levels were signiﬁcantly decreased and
partially corrected with HTx (Fig. 4). As well, homocarnosine wasFig. 5. Concentrations ofmonoamine neurotransmitters and relatedmetabolites inwhole brain
as described in Fig. 1. Additional abbreviation: 5-HT, 5-hydroxytryptamine (serotonin). Applyin
dopamine (iMSUD vs. iMSUD-HTx, p<0.001) and 3-MT (iMSUD vs. iMSUD-HTx, p<0.001) wesigniﬁcantly decreased in iMSUD brain, and corrected (actually
“hypercorrected”) in iMSUD-HTx brain (Fig. 4).
Comprehensive proﬁling of monoamine neurotransmitters and
related metabolites (Fig. 5) revealed that both dopamine and the
dopamine intermediate 3-methoxytyramine (3-MT; formed exclu-
sively in the synaptic cleft following dopamine release) were
signiﬁcantly depleted in iMSUD brain tissue and were corrected
with HTx (Fig. 5). Similarly, HTx partially corrected decreases in the
dopamine metabolic intermediate DOPAC (dihydroxyphenylacetate)
and serotonin (5-HT; 5-hydroxytryptamine) levels. Conversely,
signiﬁcantly increased 5-hydroxyindoleacetate (5-HIAA; the end-
product of 5-HT metabolism) was not responsive to HTx, and the DA
end-product homovanillic acid (HVA) was not altered in iMSUD brain
(Fig. 5).
Based upon the above monoamine abnormalities, we examined
indicators of neurotransmitter release and turnover in iMSUD brain.
Evaluation of the 3-MT/DA ratio (an indicator of cellular dopamine
release) indicated normal values in iMSUD brain (Fig. 6, left) that
remained normal following HTx. Conversely, indicators of dopamine
(DOPAC+HVA/DA) and serotonin (5-HIAA/5-HT) intracellular turn-
over revealed signiﬁcantly enhanced turnover in iMSUD brain (Fig. 6,
center and right), both of which were partially corrected with HTx.
Metabolic trends for all intermediates in iMSUD and iMSUD-HTx mice
are displayed in Table 1.. Details of the subjects studied, and statistical analyses, as described in Fig. 2. Abbreviations
g our deﬁnition of metabolic correction or partial correction (seeMaterials andmethods),
re corrected, while DOPAC and 5-HT levels were partially corrected.
Fig. 6. Estimates of cellular dopamine release (3-MT/DA; left), intracellular dopamine turnover (DOPAC+HVA/DA; center) and intracellular serotonin turnover (5-HIAA/5-HT) in
whole brain. Details of subjects studied and statistical analyses as described in Fig. 2. Applying our deﬁnition of metabolic correction or partial correction (see Materials and
methods), ratios for DOPAC+HVA/DA and 5-HIAA/5-HT were partially corrected with HTx.
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HTx has been an effective therapeutic intervention for several
inherited metabolic liver diseases, including ornithine transcarbamy-
lase (OTC) deﬁciency, alpha-1-antitrypsin deﬁciency, glycogen stor-
age disease, infantile Refsum disease and Crigler–Najjar syndrome
type 1 [6,15,16]. HTx studies in murine models have mirrored the
positive outcomes observed in clinical trials. HTx has been effective in
mouse models of phenylketonuria, tyrosinemia type I and Wilson
disease [17–19] and other small animal model systems [20,21]. Jiang
et al. [22] recently employed HTx for correction of murine hyperox-
aluria type I. However, these investigators employed tissue prepar-
ative regimens (including irradiation) that might be unlikely to obtain
IRB-approval in the clinic. Conversely, Skvorak et al. [1] demonstrated
that HTx could be achieved in neonatal iMSUD animals without
preconditioning, leading to signiﬁcant metabolic and hepatic im-
provement with only ~3% engraftment. These improvements mani-
fested as decreased total BCAA/alanine ratios in bloodspots of iMSUD-
HTx mice at weaning, associated with a 2-fold increase in liver
branched-chain ketoacid dehydrogenase activity measured at the
same age [1]. However, it is unknown if hepatic correction can lead to
metabolic improvements in other organs, including brain, or if this
metabolic correction is time-constrained.Table 1
Metabolic effects in brains of iMSUD mice following hepatocyte transplantation.
iMSUD mice iMSUD-HTx mice
Glutamate ↓ ↓
Glutamine ↓ =
Aspartate ↓ ↓
Serine ↓ ↓
Alanine ↓ ↓
Alloisoleucine ↑ ↑
Leucine ↑ ↑
Isoleucine ↑ ↑
Valine ↑ ↑
Ornithine ↑ =
GABA ↓ =
Homocarnosine ↓ ↑
Tyrosine = =
Tryptophan = =
Dopamine ↓ =
DOPAC ↓ =
3-MT ↓ =
HVA = =
5-HT (serotonin) ↓ =
5-HIAA ↑ ↑
3-MT/DA = =
DOPAC+HVA/DA ↑ =
5-HIAA/5-HT ↑ =
See text for metabolite abbreviations. All symbols represent comparisons to WT mice.
For iMSUD mice, an equals sign (=) indicates no difference fromWT mice, whereas for
iMSUD-HTx mice this symbol indicates either correction or partial correction (not
signiﬁcantly different from WT levels).Our data on amino acids and neurotransmitters in iMSUD brain
suggested a pattern of global energy disruption (Figs. 3 and4; Table 1),
as indicated by the signiﬁcant decrease of amino acid neurotransmit-
ters including glutamate, aspartate and GABA, in addition to alanine
and serine. Results for glutamate, glutamine, aspartate and GABA
were consistent with those presented by Dodd et al. in the bovine
MSUDmodel [12], and with the recently published report by Zinnanti
et al. on iMSUD animals [13]. Dodd et al. analyzed brain cortex from
neonatal MSUD calves and found that glutamate, aspartate and GABA
were uniformly reduced. We speculate that global energy dysfunction
in iMSUD brain is correlated with disrupted nitrogen balance induced
by leucine accumulation (Fig. 7), consistent with the hypotheses
recently proposed by Zinnanti et al. [13]. This hypothesis is also
consistent with the leucine–glutamate cycle as proposed by Yudkoff
[23], which posits that elevated leucine disrupts the glutamate–
glutamine–GABA cycle via increased nitrogen ﬂux associated with
transamination. Increased nitrogen loads result in 2-oxoglutarate
consumption following transamination to glutamate (see Fig. 7).
Enhanced production of 2-oxoisocaproate (the leucine transamina-
tion product) is further predicted to alter pyruvate and 2-oxoglutarate
dehydrogenase complex activity, with resulting disruption of the
oxidation/reduction potential [24–26]. Our ﬁnding of enhanced brain
ornithine levels (Fig. 3) may represent an attempt to correct depleted
levels of 2-oxoglutarate (Fig. 7) linked to dysfunction of the 2-
oxoglutarate dehydrogenase complex. This hypothesis would be
consistent with the elegantly described hypothesis of brain injury in
MSUD due to altered bioenergetics, recently put forth by Zinnanti et
al. [13]. Overall, it remains possible that disturbed glutamate/2-Fig. 7. Schematic diagram of interrelationships for selected amino acid abnormalities
identiﬁed in iMSUD mice in the current study. Note that putrescine (1,4-diaminobu-
tane) and 2-oxoglutarate were not determined in the current study. We speculate that
enhanced ammonia production from leucine transamination in brain would disrupt the
kinetics of many of the reactions depicted that utilize ammonia in catalysis, in accord
with the leucine–glutamate cycle proposed by Yudkoff.
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in MSUD patients who decompensate [27].
Concentrations of BCAAs were not improved with HTx (Fig. 3;
Table 1), consistent with blood BCAA levels previously reported [1]. As
previously suggested [1], we believe that iMSUD-HTx animals had
become catabolic, and thus protein turnover in muscle likely resulted
in signiﬁcant transport of BCAAs across the blood brain barrier in DOL
35 iMSUD-HTx animals. Two observations support this hypothesis: 1)
hyperglycinemia in iMSUD-HTx animals [1]; and 2) improved levels of
alloisoleucine both in blood [1] and brain (current study) in iMSUD-
HTx mice. Alloisoleucine is a non-protein amino acid that would not
be released during muscle protein catabolism. The cumulative
ﬁndings in Table 1 would tend to support our hypothesis of
hypercatabolism in iMSUD-HTx mice. Table 1 reveals that the major
biochemical improvements in iMSUD-HTx animals were in mono-
amine catabolic pathways, which in neural tissue might be more
compartmentalized and perhaps less affected by catabolic crises as
might be expected for amino acids such as glutamate, aspartate and
alanine.
Results for amino acid neurotransmitters (e.g., glutamate, aspar-
tate and GABA) and the GABA dipeptide homocarnosine, were of
interest. Glutamine showed partial correction with HTx, and since
glutamine is a precursor of GABA in neural tissue, this may correlate
with partial GABA correction (Fig. 4; Table 1). However, homocarno-
sine signiﬁcantly improved (Fig. 4). The reason for this remains
unclear, but it may relate to the observation that homocarnosine is a
GABA:L-histidine dipeptide. Although we found no differences in
blood or brain concentrations of histidine, it remains possible that HTx
signiﬁcantly bolstered brain concentrations of histidine within
different compartments, and this might explain the “hypercorrection”
of homocarnosine in the face of only “partial” GABA correction. Along
these lines, histidine is known to be increased in phenylketonuric
body ﬂuids [28], although the exact mechanism of this increase
remains obscure, and we have recently documented increased
histidine in blood and brain of Pah−/− mice [29]. It is possible that
histidine may be similarly elevated in iMSUD brain (in discrete
regions), and this may potentially explain the “hypercorrection” of
homocarnosine levels.
The values obtained in the current study for alanine, tyrosine and
tryptophan contrasted with data obtained by Zinnanti et al. [13] in the
same model. The latter group found alanine increased in iMSUD
animals, whereas we found this amino acid signiﬁcantly depleted in
brain (Fig. 3). This discrepancy is unlikely to have been associated
with diet (18% protein [13] vs. 22% protein in the current study) but
may have been related to age (42 days [13] vs. 20 for our animals).
Moreover, the absolute values of alanine measured in brain were
comparable between both studies (~400–600 nmol/g wet weight).
Conversely, if iMSUD animals were catabolic even at weaning, it is
possible that alanine would be utilized to generate pyruvate via
transamination; the latter would yield acetyl-CoA and oxalacetate via
the pyruvate dehydrogenase and carboxylase reactions, respectively,
which would stimulate Krebs cycle function. With respect to tyrosine
and tryptophan, the discrepancies aremore challenging to explain, yet
our normal levels for brain tyrosine (Fig. 3) were consistent with
normal amounts detected in blood of iMSUD mice, and overall the
absolute concentrations we detected were about 2-fold higher than
those measured by Zinnanti et al. (~55–70 nmol/g wet weight vs. 25–
35) for tyrosine. Concentrations of tryptophan, however, were quite
comparable between our study and the ﬁndings of Zinnanti et al. [13].
The data for monoamine metabolism in iMSUD brain reveals new
features of pathophysiology in this disorder (Figs. 5 and 6). Despite
normal tyrosine and tryptophan concentrations in brain, signiﬁcant
alterations of dopamine, DOPAC, 3-MT, 5-HT and 5-HIAA were
observed (Fig. 5). HTx corrected or partially corrected four of these.
Conversely, abnormalities in 5-HIAA levels were not corrected by HTx
(Fig. 5). Puglisi-Allegra et al. [14] reported signiﬁcant alterations inbrainmonoamines in amurinemodel of PKU, a model in which a large
neutral amino acid (e.g., phenylalanine) accumulates as for iMSUD
mice with respect to BCAAs, although Puglisi-Allegra et al. did not
report levels of tyrosine and tryptophan in the brains of their subjects.
Zinnanti et al. [13] also found that dopamine levels were depleted in
iMSUD brain. Our results are consistent with the ﬁndings of these
investigators. Lastly, although dopamine release was normal in
iMSUD brain (Fig. 6), intracellular turnover of dopamine and
serotonin was signiﬁcantly enhanced (Fig. 6) and showed partial
correction with HTx. The monoamine disturbances in iMSUD animals
occurred in the face of normal tyrosine and tryptophan concentra-
tions, however, which remain paradoxical. Metabolite quantitation
occurred in whole brain, however, and it remains possible that
regional levels (hippocampus, cortex, cerebellum, etc.) of tyrosine and
tryptophan may have been altered prior to and after HTx.
In conclusion, the current report provides new insight into
metabolic pathophysiology associated with MSUD, and proof-of-
principle that HTx can result in selected metabolic improvements in
extrahepatic organs (Table 1). As well, our ﬁndings for abnormal 5-HT
levels represent the ﬁrst demonstration of serotoninergic anomalies
associated with MSUD. The current investigation was designed as a
pilot to assess the global effect of HTx on brain neurometabolites in
the short term. Clearly, longer-term studies of iMSUD-HTx animals,
following the level of hepatocyte engraftment for several months,
while assessing neurometabolites in brain using a regional dissection
approach, are needed and planned for the near future. Nonetheless,
based upon the success thus far with OLT in MSUD [4,30] and our
positive preliminary results in iMSUD mice [1], we propose to
continue our evaluation of HTx in this model in order to generate
preclinical outcome data that could eventually support a move for this
methodology to the clinic.
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